Millennium Management’s Orchestra BioMed OBIO Stock Holding History

Millennium Management’s Portfolio OBIO Stock Details OBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.99M	Buy	702,543 +459,070	+189%	+$1.95M	﹤0.01%	3469
2025 Q4	$1.01M	Sell	243,473 -130,514	-35%	-$527K	﹤0.01%	4486
2025 Q3	$927K	Sell	373,987 -35,687	-9%	-$98.5K	﹤0.01%	4686
2025 Q2	$1.1M	Buy	+409,674	New	+$1.2M	﹤0.01%	4338
2025 Q1	–	Sell	-21,513	Closed	-$86.1K	–	6246
2024 Q4	$86.1K	Buy	+21,513	New	+$116K	﹤0.01%	5500
2023 Q3	–	Sell	-54,057	Closed	-$378K	–	6421
2023 Q2	$378K	Buy	+54,057	New	+$820K	﹤0.01%	4737
2022 Q3	–	Sell	-254,466	Closed	-$2.53M	–	7371
2022 Q2	$2.53M	Buy	254,466 +194,867	+327%	+$1.94M	﹤0.01%	3458
2022 Q1	$591K	Sell	59,599 -60,371	-50%	-$596K	﹤0.01%	4996
2021 Q4	$1.21M	Buy	119,970 +22,940	+24%	+$226K	﹤0.01%	4238
2021 Q3	$960K	Buy	97,030 +34,004	+54%	+$336K	﹤0.01%	4736
2021 Q2	$643K	Buy	63,026 +35,000	+125%	+$362K	﹤0.01%	5079
2021 Q1	$314K	Hold	28,026	–	–	﹤0.01%	5183
2020 Q4	$359K	Sell	28,026 -14,837	-35%	-$169K	﹤0.01%	4436
2020 Q3	$471	Buy	+42,863	New	+$481K	﹤0.01%	3614

Other funds holding OBIO

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

PBM

Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

DMKJ

David M. Knott Jr $168M AUM 60.36% 1-Year Est. Return

Millennium Management's OBIO Position: Q1 2026 in Review

Millennium Management increased its Orchestra BioMed (OBIO) stake by 189% in Q1 2026, buying an estimated $1.95M and bringing the position to 702,543 shares worth $2.99M. The position accounts for ﹤0.01% of the portfolio, ranked #3469.

Millennium Management first reported a position in OBIO in Q3 2020 and has held it in 14 quarters since. 65 funds tracked by Wall St. Rank hold OBIO as of Q1 2026.

Millennium Management held 702,543 shares of Orchestra BioMed worth $2.99M as of Q1 2026.
Millennium Management bought 459,070 Orchestra BioMed shares in Q1 2026, an estimated $1.95M.
Orchestra BioMed made up ﹤0.01% of Millennium Management's portfolio in Q1 2026, its #3469 holding.
Millennium Management first reported a position in Orchestra BioMed in Q3 2020 and has held it in 14 quarters since.
65 funds tracked by Wall St. Rank held Orchestra BioMed as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.